When was argenx founded?

argenx was founded in 2008 and raised its 1st funding round 1 year after it was founded.

Where is argenx located?

argenx is headquartered in Ghent, Belgium. It is registered at Boston, Massachusetts.

Who is the current CEO of argenx?

Tim Van Hauwermeiren of argenx.

How many employees does argenx have?

As of Sep 30, 2026, the latest employee count at argenx is 2341.

Is argenx a funded company?

argenx is a funded company, having raised a total of $61.9M across 11 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 09, 2009.

When was the latest funding round of argenx?

argenx's latest funding was a $***** Post IPO round on Mar 24, 2022, with participation from 0 investor.

What is the annual revenue of argenx?

Annual revenue of argenx is more than €1B as on Dec 31, 2024

Where does argenx rank among its competitors?

argenx ranks 3rd amongst 690 active competitors, of which 208 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Biogen, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of argenx?

argenx's top competitors include BeiGene, Biogen and Alexion. Among them, Biogen secured the most recent funding round in February, 2024.

argenx - 2026 Company Profile, Team, Funding, Competitors & Financials

argenx is a public company based in Ghent (Belgium), founded in 2008 by Tim Van Hauwermeiren. It operates as a Developer of antibody-based drugs to treat autoimmune diseases and cancer. argenx has raised $61.9M in funding from investors like Omnes Capital, Seventure Partners and Life Sciences Partners. The company has 690 active competitors, including 208 funded and 194 that have exited. Its top competitors include companies like BeiGene, Biogen and Alexion.

Company Details

Developer of antibody-based drugs to treat autoimmune diseases and cancer. The pipeline includes Oncology-ARGX-110, ARGX-111, ARGX-115, Autoimmunity ARGX-113, and ARGX-110. The proprietary technologies to identify the variable region from the llama's and introduces mutations in the constant region of the antibody for enhanced circulation in the system (NHance) and clearance post-therapy. The company has also developed a non-fucosylated antibody, which enhances antibody-dependent cytotoxicity.

Website: argenx.com
Email ID: *****@argenx.com
Phone Number: +32 **********
Registered Address: Boston, Massachusetts

Key Metrics

Founded Year

2008

Location

Ghent, Belgium

Stage

Public

Total Funding

$61.9M in 11 rounds

Latest Funding Round

Post IPO, Mar 24, 2022, $*****

Investors

Omnes Capital & 22 more

Ranked

3^rd among 690 active competitors

Annual Revenue

€1B+ as on Dec 31, 2024

Employee Count

2,341 as on Sep 30, 2026

Investment & Acquisitions

Forte Biosciences & 2 more

Similar Companies

BeiGene & 822 more

Exit Details

Public

View argenx's full profile

argenx is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
ARGENX US INC CIN: 364880497 , United States, Active	Dec 31, 1999	-	705 (As on Dec 31, 2024)	-
argenx CIN: 0818.292.196 , Belgium, Active	Sep 03, 2009	€1B+ (As on Dec 31, 2024)	355 (As on Dec 31, 2022)	-

argenx got listed on Jul 10, 2014.

Click here to take a look at argenx's IPO in detail

argenx has raised a total funding of $61.9M over 11 rounds. Its first funding round was on Sep 09, 2009. argenx has 23 institutional investors.

Here is the list of recent funding rounds of argenx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 24, 2022	3342863	Post IPO	5134172	5350357	1398256	4848784
May 2020	1677904	Post IPO	2580059	9652469	2548164	4505038
Nov 06, 2019	8201182	Post IPO	4533782	4709638	2007848	8444310

Access funding benchmarks and valuations. Sign up today!

View details of argenx's funding rounds and investors

The founders of argenx is Tim Van Hauwermeiren.

Here are the details of argenx's key team members:

Tim Van Hauwermeiren: Co-Founder & CEO of argenx.

View details of argenx's Founder profiles and Board Members

argenx's employee count trend

argenx has 2,341 employees as of Sep 26. Here is argenx's employee count trend over the years:

Uncover argenx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of argenx include BeiGene, Biogen and Alexion. Here is the list of Top 10 competitors of argenx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Venrock, BB Biotech & 21 others	76/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
6th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
8th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
9th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
10th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on argenx's competitors? Click here to see the top ones

argenx has made 2 investments in Unnatural Products and OncoVerity and acquired Forte Biosciences.

Here is the list of these investments and acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jul 27, 2026	Acquisition	Forte Biosciences	2017	Torrance (United States)
Mar 16, 2026	Investments	Unnatural Products	2016	Santa Cruz (United States)
Nov 22, 2024	Investments	OncoVerity	2022	Aurora (United States)